Myrelez (Lanreotide Acetate)

Lanreotide acetate, the active ingredient in Myrelez, is a somatostatin analog presented as a sterile solution for subcutaneous use. It is employed in the management of acromegaly and somatostatin receptor‑positive neuroendocrine tumors in adult patients. GNH USA supplies Myrelez as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Myrelez is a somatostatin analog used to control hormone‑driven conditions and certain tumor types. - Acromegaly: reduces excess growth hormone secretion and can shrink pituitary adenomas. - Somatostatin receptor‑positive neuroendocrine tumors: inhibits tumor growth and hormone‑related symptoms. - Carcinoid syndrome: alleviates flushing, diarrhea and other secretory manifestations associated with functional neuroendocrine tumors.

Adverse reactions may occur with any somatostatin analogue.

Common Side Effects: - Injection site pain or erythema - Nausea or vomiting - Abdominal discomfort or diarrhea - Headache - Mild hyperglycemia - Fatigue

Serious or Rare Side Effects: - Gallbladder disease or cholelithiasis - Acute pancreatitis - Severe allergic reactions (anaphylaxis, angioedema) - Cardiac arrhythmias - Significant hyperglycemia requiring medical intervention - Severe injection‑site infection or necrosis

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for known safety concerns. - Blood glucose monitoring: assess baseline glucose and watch for hyperglycemia. - Gallbladder assessment: consider ultrasonography in patients with a history of gallstones. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Renal/hepatic function: adjust use in severe impairment. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide may alter the pharmacokinetics or pharmacodynamics of several agents.

Major Interactions (Avoid): - Concomitant cyclosporine: increased risk of hyperglycemia and nephrotoxicity. - Co‑administration with other somatostatin analogues (e.g., octreotide): additive hormonal suppression. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise lanreotide exposure.

Moderate Interactions (Monitor Closely): - Antidiabetic medications: possible need for dose reduction due to altered glucose control. - Oral contraceptives: potential reduction in efficacy, monitor menstrual cycles. - Drugs metabolized by CYP2C9: monitor plasma levels for possible interaction.